Showing 161 - 180 results of 42,247 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( a ((non decrease) OR (point decrease)) ))', query time: 0.74s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180